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Letter to Blood 37 
Central nervous system (CNS) involvement in pediatric B-cell precursor acute 38 
lymphoblastic leukemia (BCP-ALL) is rarely detected at initial presentation1. 39 
Nevertheless, CNS-relapse most frequently occurs in children who were initially 40 
diagnosed as CNS-negative (CNS-) and did not have any high-risk characteristics2. 41 
Therefore all patients receive intensive CNS-directed chemotherapy3, an approach 42 
associated with short and long-term neurological toxicities4,5. The CNS 43 
microenvironment may contribute to chemoresistance and survival of leukemic 44 
cells6. Interleukin 15 (IL15) was shown to promote ALL survival in the hostile 45 
microenvironments of the CNS7,8. IL7 can be detected in the cerebrospinal fluid 46 
(CSF) and high levels have been associated with inflammatory CNS disease9, which 47 
supports that IL7 may be produced by stromal cells in that niche upon different 48 
stimuli10. Also, elevated IL7 plasma levels were detected in BCP-ALL patients11. 49 
Here we show that IL7R is highly expressed in pediatric BCP-ALL patients that were 50 
CNS+ at initial diagnosis, and that an upregulation of IL7R may predict CNS-relapse. 51 
Using a xenograft model in immunodeficient mice, we show that IL7R is required for 52 
leukemic engraftment in vivo, and that targeting IL7R with monoclonal antibody 53 
reduces CNS leukemic infiltration. 54 
 55 
The t(1;19) chromosomal translocation leading to the E2A-PBX1 fusion has been 56 
shown to increase IL7R expression12, and E2A-PBX1 rearranged BCP-ALL cells 57 
have a particular propensity to infiltrate the CNS13,14. Thus, we first analyzed IL7R 58 
expression in a cohort of 61 E2A-PBX1+ patients13 and correlated the data with 59 
clinical characteristics. IL7R expression was significantly higher in patients with an 60 
elevated white blood cell (WBC) count (Figure 1A), which is also a classical risk 61 
factor for CNS disease. Importantly, IL7R expression was also significantly higher in 62 
CNS+ as compared to CNS- patients (Figure 1B). In contrast, there were no 63 
correlations between IL7R expression and sex, age, prednisone response or minimal 64 
residual disease (MRD) risk group (Supplementary Figure 1). We next determined 65 
IL7R expression in a further cohort of 98 BCP-ALL patients of mixed molecular 66 
backgrounds. The cohort contained 26 patients that were initially CNS+ and 72 CNS- 67 
patients. There were no statistical differences in sex, age, prednisone response, 68 
MRD-risk groups and cytogenetics between both groups (Supplementary Table 1). 69 
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Importantly, IL7R expression was found to be significantly elevated in CNS+ 70 
compared to CNS- patients (Figure 1C). Multivariate analysis controlling for age and 71 
WBC count showed that IL7R expression in the third and fourth quartiles lead to 72 
odds ratios (OR) of 5.4 (95% CI 0.997-29.117) and 5.6 (95% CI 1.023-30.842) for 73 
CNS positivity, respectively (Supplementary Table 2). These data suggest that 74 
increased IL7R expression levels in BM leukemic cells are associated with and may 75 
predict CNS disease at initial diagnosis. IL7R expression also significantly correlated 76 
with ZAP70, which is another marker for CNS infiltration15, and combining both 77 
markers did not yield superior correlations, which may however be hampered by a 78 
low sample size (Supplementary Figure 2A-B). The association of IL7R expression 79 
with CNS relapse was then explored using two publicly available datasets16-18. ALL 80 
cells retrieved from the CSF of children with isolated CNS-relapse showed a 81 
significantly higher IL7R expression compared to ALL cells from BM at diagnosis and 82 
BM at BM-relapse without CNS involvement (Figure 1D). Most importantly, a high 83 
IL7R expression in BCP-ALL cells from BM/peripheral blood at diagnosis was 84 
associated with reduced long-term CNS-relapse-free probability rates in the 85 
TARGET phase 1 dataset (Figure 1E). It seems that as IL7R expression increases, 86 
reflected by increasing z-score, the rate of CNS-relapse also increases 87 
(Supplementary Figure 3A-B, Supplementary Table 3). Among different risk factors 88 
for CNS-relapse, an upregulation of IL7R was a statistically significant predictor of 89 
isolated CNS-relapse in a Cox-proportional hazards model (Supplementary Table 4). 90 
Nevertheless, increased IL7R expression was not associated with an increased risk 91 
for BM-relapse or relapses with BM involvement (Supplementary Figure 3C-D). 92 
Interestingly, there was a significant association between IL7R upregulation and 93 
E2A-PBX1 (30% of IL7R overexpressors had this translocation, Supplementary 94 
Table 5). 95 
These findings indicate that IL7R may be used as a diagnostic and prognostic 96 
marker without accessing the CNS compartment for diagnosis of CNS leukemia.  97 
 98 
We next injected 13 patient samples into NSG mice in duplicates, and mean 99 
fluorescence intensity (MFI) of IL7R was determined. Xenografts were sub-grouped 100 
into IL7RHi/IL7RLo relative to median MFI (Supplementary Table 6). CNS infiltration 101 
for 11 xenografts was analyzed13. 8/12 (67%) mice injected with IL7RHi-cells were 102 
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CNS-positive, whereas only 2/10 (20%) mice bearing IL7RLo-cells were CNS-positive 103 
(Supplementary Figure 4A). Selected IL7RHi blasts in this experiment showed a 104 
tendency to have higher basal levels of ERK, p-ERK and p-AKT compared to IL7RLo 105 
(Supplementary Figure 4B). To test whether blocking IL7R in vivo can prevent ALL 106 
engraftment and homing to the CNS, we down-regulated IL7R expression by RNA-107 
interference using an IL7Rα−specific shRNA in the human cell line 697, which 108 
expresses high levels of IL7R. Down-modulation of IL7R led to a marked decrease of 109 
blast percentages in the spleen, BM and CNS as compared to mice injected with the 110 
respective control (Figure 2A-B). To investigate whether inhibition of IL7R signaling 111 
using ruxolitinib can interfere with the engraftment of leukemic cells with a high 112 
expression of IL7R in vivo, we injected E2A-PBX1+ BCP-ALL cells from one pediatric 113 
patient into NSG mice and monitored the survival of recipient mice under ruxolitinib 114 
treatment with and without concomitant chemotherapy. We found that mice treated 115 
with ruxolitinib showed only a minor prolongation in survival in comparison to 116 
untreated control and that ruxolitinib was markedly less efficient than standard 117 
chemotherapy. In addition, ruxolitinib treatment did not decrease leukemic infiltration 118 
in the CNS (data not shown). The combination of ruxolitinib and chemotherapy did 119 
not result in additional benefits (Figure 2C). Opposite to previously published data19, 120 
our results indicate that ruxolitinib is not efficient for preventing the engraftment of 121 
human ALL cells in vivo. This might be caused by a poor bioavailability of ruxolitinib 122 
in mice and/or an insufficient inhibition of IL7R signaling, as ruxolitinib inhibits mainly 123 
JAK1/2 and not JAK3 that can be activated by IL7R signaling. Furthermore, the 124 
amount of IL7 available in vivo may have overridden the downstream inhibition by 125 
ruxolitinib. We therefore next tested whether inhibiting the IL7R with a blocking 126 
antibody would substantiate our previous findings in a further experiment with an 127 
E2A-PBX1+ patient sample in vivo. Antibody treatment significantly prolonged the 128 
survival of xenograft mice as compared to treatment with an isotype control antibody 129 
(Figure 2D). In addition, IL7R antibody treatment strongly reduced spleen size and 130 
leukemic infiltration in spleen, BM and, most importantly, in the CNS (Figure 2E-G). 131 
Ruxolitinib as a single agent or as addition to the antibody treatment had no 132 
beneficial effects (Figure 2E-G). It is worth noting that in vitro antibody treatment 133 
downmodulated IL7R signaling through AKT and induced apoptosis as indicated by 134 
an upregulation of cleaved caspase-8 (Supplementary Figure 5A-B).  135 
 6 
These findings support the view that targeting IL7/IL7R signaling may be an effective 136 
approach in BCP-ALL therapy20. So far, anti-IL7R antibodies have been investigated 137 
in preclinical mouse models of multiple sclerosis to target T cells that require IL7R 138 
expression for their homeostasis21, indicating a toxic effect of the antibody in T cells. 139 
Our study points to IL7R as a main target for BCP-ALL treatment and that further 140 
investigation of the anti-IL7R antibodies for immunotherapy of BCP-ALL may lead to 141 
improved therapeutic approaches especially for patients with CNS involvement.  142 
 143 
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Figure Legends 223 
 224 
Figure 1: IL7R expression is associated with CNS disease and CNS-relapse in 225 
pediatric BCP-ALL patients.  226 
Correlation analysis of IL7R expression in 61 E2A-PBX1 positive pediatric patients 227 
with white blood cell (WBC) count (A) and CNS status (B). Unpaired t-test, two-sided 228 
P-value. (C) Correlation analysis of IL7R expression in 98 pediatric BCP-ALL 229 
patients of mixed cytogenetics and CNS status. Further definitions are provided in 230 
Supplementary Table 1. Unpaired t-test, two-sided P-value. (D) IL7R expression in 231 
ALL cells retrieved from the CSF of 8 children with CNS-relapse of BCP-ALL as well 232 
as from the BM of 22 patients at diagnosis, and cells from the BM of 20 patients at 233 
the time of isolated BM-relapse. Dataset van der Velden et al 201616. Unpaired t-234 
test, two-sided P-value. (E) Kaplan-Meier survival curve showing reduced isolated 235 
CNS  (iCNS) relapse-free probability in children with upregulated IL7R gene 236 
expression in diagnostic BM (n=131) or peripheral blood (n=76) samples of children 237 
with high risk ALL. IL7R Upregulation was defined as a z-score for gene expression 238 
≥ 1.2; TARGET phase 1 dataset. 239 
 240 
 Figure 2: Inhibition of IL7R delays leukemogenesis in xenograft mice 241 
 (A) NSG mice were xenografted with 697 cells bearing an shRNA against the IL7Rα 242 
(shIL7Rα) or a control shRNA (shGFP). Animals were sacrificed at day 26 upon 243 
detection of >75% leukemic blasts in the peripheral blood or clinical leukemia (loss of 244 
weight or activity, organomegaly, hind-limb paralysis) in first control mice. Spleen 245 
(Sp) and bone marrow (BM) infiltration by human leukemic blasts in control and 246 
treated animals. (B) CNS infiltration as determined by histology. The arrows indicate 247 
human leukemic blasts in an example for the semiquantitative scoring employed13. 248 
(C) 1 x 106 E2A-PBX1 positive patient cells were xenografted into NSG mice. 249 
Xenografted mice were treated with vehicle only, ruxolitinib only, chemotherapy only 250 
(dexamethasone, vincristine and PEG-asparaginase) or a combination of ruxolitinib 251 
and chemotherapy (n=7 per group). Mice were sacrificed upon appearance of 252 
leukemic symptoms. Statistics for survival were performed according to the Mantel-253 
Cox log-rank method. P1: control vs. Ruxo, P2: control vs. chemo, P3: control vs. 254 
Ruxo/Chemo. (D) 1 x 106 E2A-PBX1 positive patient cells were xenografted into 255 
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NSG mice. Xenografted mice were treated with an anti-IL7R antibody or an isotype 256 
antibody (n=7 and n=6 per group, as indicated). The experiment was ended on day 257 
135. Statistics for survival were performed according to the Mantel-Cox log-rank 258 
method. (E-G) 1 x 106 E2A-PBX1 positive patient cells were xenografted into NSG 259 
mice. Xenografted mice were treated with control antibody, ruxolitinib, with an anti-260 
IL7R antibody or with both ruxolitinib and the antibody (n=7 per group). One mouse 261 
of ruxo/anti-IL7R group died during the experiment and accordingly was excluded. 262 
The experiment was ended on day 65 and spleen sizes (E), the percentages of Sp 263 
and BM blasts (F), and CNS infiltration (G) were assessed (Fisher´s exact test, two-264 
sided). Treatment protocol: 60 mg/kg of ruxolitinib (LC Laboratories) was 265 
administered Monday through Friday by oral gavage. Chemotherapy was 266 
administered as previously published15,22. 1 mg/kg of anti-IL7R antibody (monoclonal 267 
mouse IgG1, clone 40131, R&D Systems) or isotype control antibody were 268 
administered on day 0, +3, +7, +21, +35, +48 and +56 post-injection. 269 
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